Basics of Restless Legs Syndrome (Willis-Ekbom Disease)

Michael H. Silber, M.B.Ch.B.
Professor of Neurology
Mayo Clinic College of Medicine






Objectives

- Understand how RLS is diagnosed
- Understand what we know (and don't know!) about the causes of RLS
- Know which self-help approaches to RLS may be effective
- Be familiar with the drugs used to treat RLS and their side effects



The Diagnosis







ICSD-3 Criteria

Urge to move the legs,

usually but not always, accompanied or caused by unpleasant leg sensations, which:

- 1. Are present during rest or inactivity
- 2. Are partially or completely relieved by movement such as stretching or walking, as long as activity continues
- 3. Only occur or are worst in the evening and night




Additional Clinical Features

- Resultant sleep onset or maintenance insomnia
- Associated with periodic limb movements



Relationship between RLS and PLMS





Can RLS be painful?

- Yes, but first consider:
 - * arthritis
 - * fibromyalgia
 - * nocturnal leg cramps



Can RLS be asymmetric or only on one side?

- RLS may alternate between legs
- RLS may sometimes be consistently worse in one leg
- RLS may very occasionally only occur in one leg other causes or an underlying condition should be considered



Is the urge to move essential?

- Yes, this is the fundamental symptom of RLS
- Unconscious jiggling movements while sitting, easily discontinued with awareness, are learned habits, not RLS



Does relief by change in position support the diagnosis?

- Generally not
- Usually due to pressure on skin or soft tissues, especially if related to a specific leg position



Must the symptoms be relieved by movement?

- Yes, but only as long as the movement continues
- In advanced RLS, relief during movement may be less evident



What may be confused with RLS?

- Leg cramps
- Positional discomfort
- Habitual foot tapping

How Common is RLS?

1.5 - 2.7%

for RLS/WED

- at least 2 days a week
- causing at least moderate distress
 (About 1 in 50 persons will have RLS)

Allen 2010, 2011

What causes RLS?





Genes

- At least 50% of RLS is genetic
- Seems to be an autosomal dominant trait




- Association with multiple chromosomes and multiple genes.
- No comprehensive model



Dopamine

- Dopamine is a neurotransmitter in the brain associated with movement, arousal, and the reward system
- Drugs enhancing dopamine work for RLS
- The problem may be reduced dopamine receptors (the proteins which bind dopamine)





Iron

- In some patients with RLS, iron stores are reduced in the body (blood loss, frequent blood donations)
- MRI and autopsy studies show reduced iron in areas of the brain in RLS patients
- The problem may be problems transporting iron into the brain

Iron is needed for the dopamine receptor



Treatment






Intermittent RLS/WED

Definition

RLS that is troublesome enough to require treatment but occurs on an average less than twice weekly

Silber et al Mayo Clin Proc 2013





Behavioral Therapies

- Walking, stationary bicycling, rubbing or soaking limbs
- Mental alerting techniques
- Regular moderate physical activity
- Reduction in caffeine
- Consider withdrawal of antidepressants, anti-nausea meds, antihistamines



Iron?

- Do not take unless iron levels are low
- Consider for serum ferritin < 50-75 mcg/l
- Take under medical supervision twice a day between meals with Vitamin C
- Can cause indigestion, constipation and black stools
- Intravenous iron infusions are available if oral iron poorly absorbed or not tolerated
- Recheck ferritin every 3-6 months



Chronic Persistent RLS/WED

Definition

RLS which is frequent and troublesome enough to require daily therapy, usually at least twice a week causing moderate or severe distress



Chronic Persistent RLS/WED

Dopamine Agonist OR Calcium Channel Ligands

Dopamine Agonists	Calcium Channel Ligands	
Very severe RLS	Comorbid pain	
Comorbid depression	Comorbid anxiety	
Obesity/metabolic syndrome	Comorbid insomnia	
	Prior impulse control disorders or addiction	

©2015 RLS Foundation



Dopamine Agonists:

Pramipexole and Ropinirole

- Bind to dopamine receptors
- Approved by the FDA for treatment of RLS
- Trials demonstrate efficacy (>1,000 patients)
- Generics available
- Limit daily dose (much less than for Parkinson disease) (pramipexole 0.5 - 1 mg; ropinirole 4 mg)



Dopamine Agonists:

Rotigotine Transdermal Patch

- Apply once a day
- Trials demonstrate efficacy (>1,000 patients)
- Approved by FDA for RLS/WED treatment
- Skin reactions common



How successful are the dopamine agonists?

Much or very much improved:

Pramipexole: 59-75%

• Ropinirole: 53-68%

• Rotigotine: 50-75%

Oertel 2007, 2008; Winkelman 2006; Trenkwalder 2004, 2008; Walters 2004; Ferini-Strambi 2008; Giorgi 2013; Inoue 2013



Long Term Follow Up

	Pramipexole	Pramipexole	Rotigotine
Patients	50	164	295
% on drug after 5 years	90	58	43
% on drug after 10 years	82	25	-
	Lipford 2012	Silver 2011	Oertel 2011

©2015 RLS Foundation



Dopamine Agonists

Mild Side Effects

- Lightheadedness
- Nausea or indigestion
- Nasal congestion
- Leg swelling
- Sleepiness



Dopamine Agonists

Serious Side Effects

- Augmentation
- Impulse control disorders



Augmentation

Development of worsening RLS with increasing doses of dopaminergic medication

- Earlier onset symptoms (2-4 hours+)
- Spread to arms or trunk
- Shorter duration of response to medication



Augmentation (10 year studies)


164 patients on pramipexole

10 years follow-up

Discontinuation rate due to augmentation:

7% per year

Silver 2011






Augmentation (10 year studies)

50 patients on pramipexole

Median follow-up 9.7 yrs

Augmentation rate 42%

Lipford 2012





Augmentation (5 year study)

295 patients on Rotigotine

Augmentation rate 36%

Discontinuation rate due to augmentation 4%

Oertel 2011



Impulse Control Disorders

Any ICD

Pathologic gambling

Compulsive shopping

Hypersexuality

17% (control 6%)

9% (control 0.4%)

5% (control 0.7%)

3% (control 0.4%)

Mean time of onset after starting therapy: 9 months

Cornelius Sleep 2010



Calcium Channel Ligands

- Gabapentin
- Gabapentin Enacarbil (slow release; once a day)
- Pregabalin

Side-Effects: sleepiness, dizziness, unsteadiness, weight gain, depression



Calcium Channel Ligands

- Only gabapentin enacarbil FDA approved for RLS
- Study showed pregabalin as effective as pramipexole, but more side effects
- No augmentation



Augmentation

- Check ferritin
- Split agonist dose, cautiously increase total dose watching for progressive augmentation and not exceeding recommended total daily dose
- Change to rotigotine
- Change to a calcium channel ligand



Refractory RLS/WED

Definition

RLS unresponsive to monotherapy with tolerable doses of 1st line agents due to reduced efficacy, augmentation or side effects



Refractory RLS/WED

- Reassess iron stores
- Use combination therapy: Reduce the dose of the first line agent and add one or more alternative agents (e.g. calcium channel ligand to agonist)
- Substitute a medium or high potency opioid



Opioids

- Very effective for refractory RLS
- 2% serious side-effects (vomiting, constipation, ileus)
- Persistent benefit up to 10 years
- Prescribed drugs include oxycodone, methadone and others



Opioid Side Effects

- Itch
- Constipation
- Nausea and vomiting
- Cognitive effects
- Gait unsteadiness and falls
- Sleep apnea
- Overdose
- Addiction



Opioid Rules

- No early refills
- No replacements for lost prescriptions or drugs
- No changes in regime without discussion with provider
- Opioids from only one provider
- Random urine drug screens
- Use of state prescription monitoring programs
- Frequent reassessment of response and side effects

